1-2 of 2
Tapan Nayak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy

Free
Benjamin Ribba, Christophe Boetsch, Tapan Nayak, Hans Peter Grimm, Jehad Charo, Stefan Evers, Christian Klein, Jean Tessier, Jean Eric Charoin, Alex Phipps, Pavel Pisa, Volker Teichgräber
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (14): 3325–3333.
https://doi.org/10.1158/1078-0432.CCR-17-2953
Published: 15 July 2018
View article titled, Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Open the PDF for Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Free
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, Christophe Massard, Elena Garralda, Valentina Boni, Alvaro Taus, Joan Albanell, Marie-Paule Sablin, Marie Alt, Ratislav Bahleda, Andrea Varga, Christophe Boetsch, Izolda Franjkovic, Florian Heil, Angelika Lahr, Katharina Lechner, Anthony Morel, Tapan Nayak, Simona Rossomanno, Kevin Smart, Kay Stubenrauch, Oliver Krieter
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1536–1545.
https://doi.org/10.1158/1078-0432.CCR-17-1588
Published: 02 April 2018
View article titled, First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data